DOJ Clarifies Position On Fraud-On-The-FDA Theory Of False Claims Act Liability - Life Sciences, Biotechnology & Nanotechnology
On June 3, 2022, the Washington, D.C., office of the Civil Division of the Department of Justice (DOJ) filed a statement of interest in a relator's action